Sepsis Therapeutics Market Size, Share, Trends, Growth, Consumption, Production, Revenue and Forecast 2020 - 2027

In terms of revenue, the global sepsis therapeutics market is projected to expand at a CAGR of 7.3% during the forecast perio 2020 to 2027 and to reach valuation of around US$ 6.1 billion by 2027.

Sepsis, also known as septicemia, is a life-threatening disease caused when the body responds to an infection. Sepsis leads to a series of reactions that causes widespread inflammation throughout the body, and could result in septic shock, a medical emergency. Healthcare reimbursements are reforming significantly, which inclines patients toward better treatment regimens. Increase in the number of products in the pipeline and rise in research & development expenditures are expected to be the leading factors boosting the growth of the sepsis therapeutics market.

A Key Driver

• The geriatric population is prone to developing sepsis, and is expected to increase the patient pool across the world, which, in turn, is projected to drive the sepsis therapeutics market during the forecast period.
• According to the United Nations University (UNU), the percentage of the world population above 65 years of age is anticipated to increase from 9% in 2010 to 16% by 2050.
• Rise in the epidemiological burden of sepsis increases the demand for the development of drugs for the treatment of sepsis. This is likely to boost the growth of the sepsis therapeutics market.
• Leading pharmaceutical companies are striving to address these unmet medical needs through new product development.
• Asahi Kasei Corporation is planning to launch ART-123 by 2021 for the treatment of sepsis. The drug has shown positive results for phase III clinical trial for sepsis, which would support the advancement of drugs for phase IV studies.
• New approval and commercialization of novel therapeutic drugs under clinical trial studies are projected to be a major driver of the global sepsis therapeutics market from 2019 to 2027.

Cephalosporin Drug Class and Intravenous Route of Administration to Dominate Sepsis Therapeutics Market

The cephalosporin segment accounted for the largest share of the global sepsis therapeutics market in 2019. The segment is projected to dominate the global market from 2020 to 2027. Additionally, the segment is expected to expand at a significant CAGR during the forecast period. Third-generation cephalosporins (e.g. cefotaxime) represent a reasonable alternative to aminoglycoside. Hence, the segment is likely to dominate the sepsis therapeutics market during the forecast period. However, the segment is expected to lose market share during the forecast period, due to development of antibiotic resistance against cephalosporin by pathological agents. According to the World Health Organization, more than 30 million people are affected by sepsis across the world every year, while 6 million people die from the disease. Hence, rise in the epidemiological burden of sepsis increases the demand for the development of intravenous drugs, which is likely to propel the intravenous segment during the forecast period.

Retail Pharmacies Hold Significant Share in Sepsis Therapeutics Market

The retail pharmacies segment dominated the market in terms of distribution channel in 2019. Factors such as rise in affordability of patients and increase in number of retail pharmacies are expected to fuel the growth of the segment in the near future. The retail pharmacies segment is expected to expand at a high CAGR during the forecast period. Globally, around 84% pharmacies are retail pharmacies. The easy accessibility to retail pharmacies leads to the easy availability of drugs. This is expected to propel the retail pharmacies segment from 2020 to 2027.

Immunometabolism Delivers Insights on New Therapeutic Targets

Healthcare companies in the sepsis therapeutics market are increasing research on immunometabolism, as insights on immune regulation are helping manufacturers develop efficacious drugs. Since the early detection and treatment of sepsis is critical, researchers are studying the body’s natural and innate response to various classes of drugs by studying immunometabolism. To gain further insights, healthcare companies are running clinical trials involving antibiotics, fluids, and dialysis, to ensure blood flow to the affected organs. They are also devising methods of surgical therapies to remove damaged tissues.

As such, healthcare companies in the sepsis therapeutics market are trying to identify new therapeutic targets that could potentially reduce inflammatory response in patients. They are increasing research via animal testing by introducing lipopolysaccharide (LPS) in mice to see if the molecule can suppress the severity of inflammatory response.

Judicious Prescriptions and New Antimicrobial Agents Reduce Drug Resistance

Antimicrobials have a rapid and long-lasting effect on septic infections. However, antimicrobial resistance to gram-positive infections (GPIs) is emerging as a major public health threat to patients, worldwide. The growing prevalence of multidrug-resistant bacteria in patients has led to increased morbidity and mortality rates. This has created the issue of escalated treatment costs and prolonged hospitalization stay for patients. This is why, healthcare companies in the sepsis therapeutics market are developing new antimicrobial agents to reduce the resistance of drugs against gram-positive infections.

Healthcare companies are expected to develop a robust healthcare value and supply chain in the Asia Pacific region, as it is predicted for fast growth in the sepsis therapeutics market. For instance, stakeholders in the sepsis therapeutics market have observed the growing prevalence of methicillin resistant staphylococcus aureus bacteria in Indian patients that has led to the heavy consumption of antibiotics. Thus, stakeholders in the sepsis therapeutics market are recommending judicious prescription of antimicrobial agents, implementation of antibiotic stewardship programs, and conformation to suitable antibiotic policies developed by health commissions to reduce the problem of drug resistance in patients.

Asia Pacific to Create High Incremental Opportunity

In terms of revenue, North America is projected to dominate the global sepsis therapeutics market from 2020 to 2027. This can be ascribed to a large patient pool in the region requiring efficient and new therapies. The sepsis therapeutics market in Asia Pacific is expected to expand at a relatively high CAGR during the forecast period, owing to increase in the focus on the development of healthcare infrastructure by governments and rise in the demand for the affordability of therapeutics in a significant base of patient population. Additionally, wide scope of development and rapid urbanization offer significant opportunities to emerging as well as established players in the region. This, in turn, drives the sepsis therapeutics market in Asia Pacific.

Key players operating in the global sepsis therapeutics market include -

• INOTREM S.A.
• Mylan N.V.
• Asahi Kasei Corporation
• Pfizer, Inc.
• GlaxoSmithKline plc
• RegeneRx
• Adrenomed AG
• AtoxBio
• Endacea, Inc.

Market Segmentation

By Drug Class

• Aminoglycosides
• Cephalosporin
• Glycopeptide Antibiotics
• Others

By Route of Administration

• Intravenous
• Oral

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • U.K.
  • Italy & Spain
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • ASEAN
  • Rest of Asia Pacific
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America

Scope of the Report

A new study conducted on the global sepsis therapeutics market was published by Vision Research Reports It presents a whole wealth of information on the key market dynamics, including the drivers, market trends, and challenges, as well as the structure of the sepsis therapeutics market. VRR’s study offers valuable information about the sepsis therapeutics market, to illustrate how growth will discern during the forecast period of 2020 - 2027.

Key indicators of market growth, which include pipeline analysis and Compound Annual Growth Rate (CAGR), have been elucidated in VRR’s study in a comprehensive manner. This data can help readers interpret the quantitative growth aspects of the sepsis therapeutics market for the duration of the forecast period.

An extensive analysis on leading market players’ business strategies is also featured in VRR’s study on the sepsis therapeutics market. This can help readers understand principal factors to foresee growth in the sepsis therapeutics market. In this study, readers can also find specific data on the qualitative and quantitative growth avenues of the sepsis therapeutics market, which will guide market players in making apt business decisions in the future.

Key Questions:

• What is the scope of growth of sepsis therapeutic companies in the pharmaceutical drugs sector?
• What will be the Y-o-Y growth of the sepsis therapeutics market between the years 2020 and 2027?
• What is the influence of the changing trends in the sepsis therapeutics market?
• Will North America continue to remain the most profitable regional market for sepsis therapeutic providers?
• Which factors will hamper the growth of the sepsis therapeutics market during the forecast period of 2020 to 2027?
• Which are the leading companies in the global sepsis therapeutics market?

Research Methodology

A unique research methodology is utilized by VRR to conduct comprehensive research on the sepsis therapeutics market, and arrive at conclusions on the future growth prospects of the said market. This research methodology is a combination of primary and secondary research, which helps analysts warrant the accuracy and reliability of the drawn conclusions.

Secondary resources referred to by analysts during the production of the sepsis therapeutics market report include statistics from company annual reports, SEC filings, company websites, World Bank database, investor presentations, regulatory databases, government publications, and industry white papers. Analysts have also interviewed senior managers, product portfolio managers, CEOs, VPs, and market intelligence managers, all of whom contributed to the production of VRR’s study on the sepsis therapeutics market, as a primary resource.

These primary and secondary resources provided exclusive information during the interviews, which serves as a validation from sepsis therapeutics market industry leaders. Access to an extensive internal repository and external proprietary databases allows for this report to address specific details and questions about the sepsis therapeutics market with high accuracy. The study also uses a top-down approach to assess the numbers for each segment, and a bottom-up approach to counter-validate them. This has helped in making VRR’s estimates on the future prospects of the sepsis therapeutics market much more reliable and accurate.